Marine Drugs · 2013 · 29 citations · 31 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCell Cycle PharmacologyMalignant NeoplasmsOncogenic Signaling PathwaysCancer Cell Proliferation InhibitionCancer Signaling PathwaysErk SignalingMap KinasesP21 PathwayP21 RegulationRaf-mek-erk SignalingTime-dependent Inhibition
Here we first demonstrate that asperolide A, a very recently reported marine-derived tetranorditerpenoid, leads to the inhibition of NCI-H460 lung carcinoma cell proliferation by G2/M arrest with the activation of the Ras/Raf/MEK/ERK signaling and p53-dependent p21 pathway. Treatment with 35 μM asperolide A (2 × IC(50)) resulted in a significant increase in the proportion of G2/M phase cells, about a 2.9-fold increase during 48 h. Immunoblot assays demonstrated time-dependent inhibition of G2/M regulatory proteins. Moreover, asperolide A significantly activated MAP kinases (ERK1/2, JNK and p38 MAP kinase) by phosphorylation, and only the inhibition of ERK activation by PD98059 reversed downregulation of G2/M regulatory proteins CDC2, and suppressed upregulation of p21 and p-p53 levels. Transfection of cells with dominant-negative Ras (RasN17) mutant genes up-regulated asperolide A-induced the decrease of cyclin B1 and CDC2, suppressed Raf, ERK activity and p53-p21 expression, and at last, abolished G2/M arrest. This study indicates that asperolide A-induced G2/M arrest in human NCI-H460 lung carcinoma cells relys on the participation of the Ras/Raf/MEK/ERK signaling pathway in p53-p21 stabilization. An in vivo study with asperolide A illustrated a marked inhibition of tumor growth, and little toxcity compared to Cisplatin therapy. Overall, these findings provide potential effectiveness and a theoretical basis for the therapeutic use of asperolide A in the treatment of malignancies.
31
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Bert Vogelstein, David P. Lane, Arnold J. Levine · Nature · 2000 · 6.6K citations
Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis
Zhengui Xia, Martin Dickens, Joël Raingeaud et al. · Science · 1995 · 5.3K citations
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina, Ping Yang, Stephen D. Cassivi et al. · Mayo Clinic Proceedings · 2008 · 2.9K citations
Requirement for p53 and p21 to Sustain G <sub>2</sub> Arrest After DNA Damage
Fred Bunz, Annie Dutriaux, Christoph Lengauer et al. · Science · 1998 · 2.8K citations